AN2 Therapeutics (ANTX) Status update summary

Strategic rationale and market opportunity

• Epetraborole is being advanced into polycythemia vera (PV) based on compelling data from non-PV patients, aiming to address a significant unmet need for oral, red cell-specific therapies.

• The U.S. PV market is estimated at 150,000–155,000 patients, representing a substantial opportunity, with phase II trial initiation planned for Q3 2026 and initial data expected in Q4 2026, followed by updates through 2027.

• Current PV treatments, including phlebotomy and cytoreductive agents, often fail to maintain hematocrit below 45%, highlighting the need for new options.

• Durable hematocrit control is challenging with existing therapies, and no oral therapies specifically target erythrocytosis.

Clinical data and trial design

• Epetraborole demonstrated consistent, dose-dependent, and reversible hematocrit reduction in phase I, II, and II/III studies, with minimal impact on white blood cells and platelets.

• The phase II trial will include open-label and placebo-controlled cohorts, dose optimization, and an optional extension, focusing on phlebotomy-dependent PV patients.

• Key objectives are to assess efficacy, optimize dosing, evaluate safety and tolerability, and measure patient-reported outcomes.

• Real-time data will be collected on hematocrit control, pharmacokinetics, phlebotomy requirements, and safety, with enrollment of 40–50 patients across multiple sites.

• Initial sentinel cohort data are expected in Q4 2026, with ongoing updates through 2027.

Mechanism of action and differentiation

• Epetraborole is hypothesized to inhibit globin synthesis, selectively blocking red blood cell production at a specific marrow stage, with reversible effects and minimal risk of cytopenias.

• Unlike current therapies, epetraborole is oral, red cell-specific, and does not significantly lower other blood counts, potentially reducing side effects and improving patient quality of life.

• Once-daily oral administration and objective endpoints enable timely data readouts and flexible titration.